TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04478721
Drug: Temocillin
Normalized name: temocillin
DrugBank: Temocillin (DB12343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention of experimental arm will be Intravenous administration of temocillin.
Study: NCT04478721
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention of comparator arm will be intravenous administration of meropenem.
Study: NCT04512196
Drug: Superoxidized Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super-oxidized solution contains hypochlorous acid (HOCl) which exhibits bactericidal activity. These reactive species create an imbalanced osmotic gradient which damages the cell membrane integrity of single celled organisms, and subsequently denaturing its lipid and protein content. Multicellular organisms including host tissue are not susceptible to such changes in osmolarity hence spared from damage.
Study: NCT00687843
Drug: Tegafur-gimeracil-oteracil potassium (TS-1)
Normalized name: tegafur
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8
Study: NCT03461952
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240mg
Study: NCT03461952
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1mg/kg
Study: NCT01931475
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02794792
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral
Study: NCT00806663
Drug: sunitinib added to FOLFIRI
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sunitinib 37 mg once daily (4 weeks on/2 weeks off)
Study: NCT00596817
Drug: Vortioxetine (Lu AA21004)
Normalized name: Vortioxétine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: encapsulated tablets, daily, orally
Study: NCT01654718
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole 40mg Delayed release tablets (Test Product)
Study: NCT01654718
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protonix® Delayed Release 40 mg tablets (Reference product)
Study: NCT00155272
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03219840
Drug: Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
Study: NCT03219840
Drug: Xylitol only chewing gum
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
Study: NCT01678131
Drug: Vaniprevir 300 mg
Normalized name: Vaniprevir
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vaniprevir capsules were administered orally, twice per day to achieve a final daily dose of 300 mg on Days 1 through 6; and a single dose of 300 mg, orally, on Day 7.
Study: NCT01175096
Drug: RAD001 (everolimus, Afinitor®)
Normalized name: everolimus 10 MG [Afinitor]
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RAD001 will be provided by Novartis to the study sites. RAD001 is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 30 tablets. The study site will dispense an adequate supply of RAD001 to the patient for self-administration at home.~2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day, One treatment cycle consists of 28 days.
Study: NCT06253364
Drug: PD-1 monoclonal antibody and lenvatinib
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjuvant PD-1 group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.~Adjuvant PD-1 plus Lenvatinib group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV 21 days for 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.
Study: NCT00443079
Drug: IdB 1016 (Siliphos)
Normalized name: Eliphos
DrugBank: Calcium acetate (DB00258)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 pill 3 times daily x 6 weeks
Study: NCT03152084
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.
Study: NCT03356080
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine,iv,0.1-0.2mg/kg, Day1-Day3 per week,up to 3 weeks
Study: NCT03356080
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cytarabine, iv,15mg/m2 q12h, Day1-Day10
Study: NCT03356080
Drug: All-transretinoic acid
Normalized name: (all-Z)-4,7,10,13,16-docosapentaenoic acid
DrugBank: Osbond acid (DB14088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All-transretinoic acid, 45mg/d Day4-Day6;15mg/d Day7-Day20
Study: NCT03356080
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF 300ug,sc,Day 0 until CR is achieved
Study: NCT00546065
Drug: esomeprazole treatment
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: concomitant esomeprazole treatment
Study: NCT01054092
Drug: ipragliflozin
Normalized name: ipragliflozin
DrugBank: Ipragliflozin (DB11698)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: oral
Study: NCT01901601
Drug: Retrobulbar Block or General Anesthesia
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00716014
Drug: TD101
Normalized name: TD101
DrugBank: TD101 (DB06596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TD101 is injection into a callus on the bottom of one of the patient's feet
Study: NCT00716014
Drug: Normal saline (placebo)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A normal saline solution (placebo) is injected into one of the patient's feet.
Study: NCT00691912
Drug: Myocet / Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
Study: NCT04292912
Drug: GSK2798745
Normalized name: GSK2798745
DrugBank: GSK2798745 (DB16033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2798745 will be administered.
Study: NCT03106363
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol to tonic water to obtain a target blood alcohol content of 0.08mg%.
Study: NCT00468221
Drug: Ozone Exposure
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ozone exposure in chamber
Study: NCT00280397
Drug: E7080
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.
Study: NCT01578473
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral softgel 2000 IU once daily 9 months
Study: NCT01578473
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral softgels 400 IU and 200 IU 1 softgel of 400 IU daily~1 softgel of 200 IU daily 9 months
Study: NCT04398589
Drug: Dexmedetomidine injection
Normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.
Study: NCT04398589
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.
Study: NCT00490789
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: daily oral sirolimus with dosage individualised by trough blood levels
Study: NCT00659373
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00659373
Drug: triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04517201
Drug: iNCDSS based insulin regime
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
Study: NCT04517201
Drug: Physician based insulin regime
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients of this group will receive the insulin regime recommended by professional endocrinologists.
Study: NCT00905593
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03618173
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone at the dose of 0,2mg/kg = 0,2mL/kg of a solution of 1mg/mL max 8mg
Study: NCT00665262
Drug: tramacet
Normalized name: triamcinolone acetonide Injectable Suspension [Tramacort]
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 tablets every 6 hours for 5 days
Study: NCT00659373
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04141501
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of psilocybin (25mg). orally in form of a capsule
Study: NCT03781635
Drug: bolus of intravenous ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low-dose ketamine (0.25mg.kg-1) is administered intraoperatively as bolus at incision (T0) and for each hour of anesthesia untel the end of surgery.
Study: NCT03781635
Drug: continuous infusion of intravenous ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An infusion of low-dose ketamine (0.25 mg.kg-1.h-1) is started at T0 (incision) with an infusion pump and is kept at the same rate until the end of surgery
Study: NCT02097238
Drug: Eribulin Mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01989143
Drug: PF-06480605
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single intravenous doses of 1, 3, 10, 30, 100, 300, 600 or 800 mg of PF-06480605 solution in a dose escalation format.
Study: NCT04138472
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.
Study: NCT04138472
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
Study: NCT01989143
Drug: PF-06480605
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive three subcutaneous doses of 30, 100, or 300 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
Study: NCT01989143
Drug: PF-06480605
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive three intravenous doses of 500 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
Study: NCT01607320
Drug: Raloxifene
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal
Study: NCT02973724
Drug: Propofol anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 μg/ml.
Study: NCT02993250
Drug: AL-335
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AL-335 800 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
Study: NCT02993250
Drug: Odalasvir (ODV)
Normalized name: ODV
DrugBank: Odalasvir (DB13041)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ODV 25 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
Study: NCT02993250
Drug: Simeprevir (SMV)
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive SMV 75 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
Study: NCT02821338
Drug: Lamotrigine Extended Release
Normalized name: lamotrigine Extended Release Oral Tablet
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
Study: NCT01607320
Drug: Clomiphene
Normalized name: Clomiphene
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal
Study: NCT00059826
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT00059826
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT00351026
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: short-term methadone maintenance
Study: NCT01421823
Drug: alpha agonist ointment
Normalized name: alpha tocopherol
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks local treatment with alpha agonist ointment
Study: NCT04081610
Drug: lagricel ofteno multidose
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Dosage: 1 drop 4 times a day per 7 days, both eyes~* Route of administration: Ophthalmic
Study: NCT04081610
Drug: lagricel ofteno single dose
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Dosage: 1 drop 4 times a day per 7 days, both eyes~* Route of administration: Ophthalmic
Study: NCT00713258
Drug: Parathyroid hormone (PTH) (1-84)
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 µg PTH(1-84) daily
Study: NCT00713258
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 mg alendronate weekly
Study: NCT01786135
Drug: SGN-CD19A
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
Study: NCT01063621
Drug: KW-6500
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 1 to 6 mg for the OFF state during 52 weeks
Study: NCT02257489
Drug: ACE-083
Normalized name: albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant fusion protein
Study: NCT03239860
Drug: GNbAC1 Monoclonal Antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly IV
Study: NCT00066794
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ind: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-74 consol: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-50
Study: NCT00066794
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ind: 200 mg/m2/d cont IV days 2-74
Study: NCT00066794
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ind: 45 mg/m2/d cont IV days 2-74
Study: NCT01972438
Drug: ASEDs
Normalized name: GT-AS
DrugBank: GT-AS (DB17883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Intervention
Study: NCT01972438
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control Intervention
Study: NCT01161368
Drug: Lapatinib, Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly \[Days 1 and 8\] for 2 weeks, followed by a rest week in a 3-week cycle.
Study: NCT00552084
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplements 4 gms will be taken daily for 24 weeks.
Study: NCT00557011
Drug: Adderall XR
Normalized name: Adderall XR
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg capsules taken once daily in the morning at dosages of either 1x10mg, 2x10mg or 3x10mg
Study: NCT03348930
Drug: Tolcapone 200 MG
Normalized name: tolcapone 200 MG
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All eligible study subjects will go through a 2-week treatment phase during which they will begin tolcapone at 100mg twice a day.
Study: NCT01597414
Drug: Pertuzumab + trastuzumab
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab: loading dose of 8 mg/kg of body weight on cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks.~Pertuzumab: loading dose of 840 mg on cycle 1, followed by 420 mg for subsequent cycles, every 3 weeks.~if T-DM1: 3.6 mg/kg IV, every 3 weeks.
Study: NCT01597414
Drug: Pertuzumab + trastuzumab + metronomic chemotherapy
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab and trastuzumab will be administered as in arm A. Cyclophosphamide: daily dose of 50 mg/day. if T-DM1: as in arm A
Study: NCT04061512
Drug: Dexamethasone, cyclophosphamide, rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: DRC Arm (chemotherapy) consists of dexamethasone, cyclophosphamide and rituximab treatment
Study: NCT04061512
Drug: Rituximab, ibrutinib
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RI Arm (chemotherapy free) consists of rituximab and ibrutinib treatment
Study: NCT03169881
Drug: Darbepoetin
Normalized name: Darbepoetin
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin 10 micrograms/kg/once every week (IV or SC). Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
Study: NCT05088174
Drug: Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule
DrugBank: Hetrombopag (DB16184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug:~Hetrombopag Olamine Tablet Ciclosporin Soft Capsule
Study: NCT00936143
Drug: infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg/bottle 5mg/kg inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
Study: NCT05338502
Drug: Selpercatinib
Normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT02356198
Drug: EXPAREL
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transversus abdominis plane injection
Study: NCT05338502
Drug: Ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02356198
Drug: Intrathecal hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal opioid administration
Study: NCT05338502
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00436475
Drug: Vitamin D3 2,000 IU orally once daily
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 2,000 IU orally once daily
Study: NCT00436475
Drug: Vitamin D3-Placebo
Normalized name: vitamin D3
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3-Placebo
Study: NCT02065375
Drug: Omaveloxolone Ophthalmic Suspension 1.0%
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02065375
Drug: Omaveloxolone Opthalmic Suspension 0.5%
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03024957
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces with injection of morphine sulphate .
Study: NCT03024957
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
Study: NCT03024957
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.